Hepatitis B Topics HBV Disease Progression
Blood Test Could Help Predict Which Hepatitis B Patients Will Develop Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 09 June 2016 00:00
- Written by Thomas Jefferson University
A blood test that measures a set of circulating microRNAs (miRNAs) may help identify who will develop hepatitis B virus-related hepatocellular carcinoma (HCC), a type of primary liver cancer, according to research published in the May 24 online edition of OncoTarget.
Cancer Is Falling Overall But Liver Cancer Is Rising, Largely Due to Hepatitis B and C
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 15 March 2016 00:00
- Written by Liz Highleyman
Overall cancer rates have declined significantly in the U.S. over the past decade thanks to better screening and prevention, with the notable exception of liver cancer, according to a new Annual Report to the Nation on the Status of Cancer. A majority of liver cancer is caused by hepatitis B virus (HBV), which is preventable with a vaccine, or hepatitis C virus (HCV), which can now be cured in most cases.
Antiviral Treatment for Hepatitis B Improves Liver Function after Decompensation
- Details
- Category: Approved HBV Drugs
- Published on Thursday, 09 July 2015 00:00
- Written by Liz Highleyman
Early treatment with antiviral therapy can restore liver function and increase survival in chronic hepatitis B patients with decompensated cirrhosis who might otherwise need a liver transplant, according to a Korean study published in the June 2015 issue of Hepatology.
Hepatitis B Vaccine, Hepatitis C Treatment Could Prevent Most Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 04 February 2016 00:00
- Written by World Hepatitis Alliance
Widespread vaccination against hepatitis B virus (HBV) and prompt treatment of chronic hepatitis C virus (HCV) -- which together are the most common cause of hepatocellular carcinoma -- could prevent an estimated 80% of liver cancer deaths, according to the World Hepatitis Alliance in an announcement commemorating World Cancer Day.
ASCO 2015: PD-1 Checkpoint Inhibitor Nivolumab Shows Promise against Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 02 June 2015 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor nivolumab (Opdivo) was a star of the show at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago, with study results showing that the drug demonstrated anti-tumor activity against hepatocellular carcinoma in a Phase 1/2 study, along with further Phase 3 evidence of its effectiveness against lung cancer and melanoma.
AASLD 2015: Coffee Linked to Reduced Liver Fibrosis in People with HBV, HCV, and NAFLD
- Details
- Category: Fibrosis & Cirrhosis
- Published on Wednesday, 25 November 2015 00:00
- Written by Liz Highleyman
Drinking coffee was associated with lower liver stiffness -- a non-invasive measure used to estimate liver fibrosis -- in people with hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD), researchers reported at the 2015 AASLD Liver Meeting last week in San Francisco. The study also showed a trend toward less liver fat build-up in people with NAFLD.
EASL 2015: HBV Patients on Long-term Entecavir or Tenofovir Have Low Mortality, HCC Still a Risk
- Details
- Category: HBV Disease Progression
- Published on Wednesday, 27 May 2015 00:00
- Written by Liz Highleyman
More than 95% of people with chronic hepatitis B were still alive after 5 years on antiviral therapy with entecavir (Baraclude) or tenofovir (Viread), and most deaths were due to non-liver-related causes, but hepatocellular carcinoma was still a major factor affecting mortality, researchers reported presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
More Articles...
- EASL 2015: Prenylation Inhibitor Lonafarnib Lowers Hepatitis Delta Viral Load During Therapy
- Everolimus Did Not Improve Survival for Advanced Liver Cancer Patients
- EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse
- EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment
- Increased Distance Reduces Likelihood of Liver Transplant
Web Design and Development by